Aurora BioPharma To Present Promising CAR T Cell Therapy Clinical Data in Glioblastoma at BIO Investor Forum
CAMBRIDGE, MA - September 24, 2015 - Aurora BioPharma, Inc. announces its CEO, Robert Brooks, will present promising CAR T Cell Therapy clinical data in Glioblastoma at the BIO Investor Forum taking place at the Parc 55 Hilton Hotel in San Francisco on October 20-21, 2015.
Aurora will present promising clinical data with CAR T Cell Therapy from a Phase 1 trial in Glioblastoma, a deadly type of brain cancer. The CAR T cell agent AU-105 met its endpoints of safety and anti-tumor efficacy, in addition to achieving a very encouraging signal of increased median overall survival. The National Cancer Institute estimates about 23,000 people will be diagnosed with brain cancer, and nearly 14,000 people will die from the disease this year. Most notably, Glioblastoma claimed the lives of Vice President Joe Biden’s son, Beau Biden, and Senator Ted Kennedy.
About Aurora BioPharma, Inc.
Aurora is a biotechnology company based in Cambridge, Massachusetts commercializing cutting-edge cancer immunotherapy drugs in FDA human clinical trials. Aurora's portfolio includes Chimeric Antigen Receptor T-cell therapy (CAR T) in preclinical and clinical trials in liquid as well as solid tumors. Aurora's team is comprised of experienced leading research scientists and business professionals with successful track records in the industry.
Aurora BioPharma also has an equity interest in MedVax Technologies, Inc. that is developing cancer vaccines: MX-225, an autologous Adenovirus P53 dendritic cell vaccine that has completed two FDA Phase II(a) clinical trials, in Small Cell Lung Cancer, and the company is planning a combination trial with a PD-1 antibody in lung cancer in collaboration with a major pharmaceutical company. MX-225 is also in a Phase II combination trial at Moffitt Cancer Center in breast cancer with Indoximod, an IDO inhibitor. And MX-402, a HER2 Peptide vaccine that in a Phase I trial in solid tumors.
About Bio Investor
The gathering focuses on early and established private and public companies. The global gathering attracts over 600 corporate executives, venture capitalists, public market investors and research analysts from 21 countries. The conference offers networking opportunities for the leaders of these global pharmaceutical and biotechnology companies to participate in One-on-One Partnering.
BIO is the world's largest trade association representing biotechnology companies, state biotechnology centers and academic institutions in the United States and in more than 30 nations. BIO members include corporate leaders representing Fortune 500 multinationals in the research and development of innovative healthcare, industrial and environmental biotechnology products. BIO also produces BIO International, the world’s largest biotechnology gathering.
Cautionary Note on Forward-Looking Statements
This press release and any statements of representatives and partners of Aurora BioPharma, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
For media inquiries, please contact:
VP, Business Development & Public Relations
Aurora BioPharma, Inc.
Harvard Square, One Mifflin Place, Suite 400
Cambridge, MA 02138
Tel: 617-674-7718 - Fax: 617-674-7701
Ingraham Building, 25 SE 2nd Avenue, Suite 504
Miami, FL 33131
Tel: 305-371-2301 - Fax: 305-371-2301
email@example.com - www.aurorabiopharma.net
- New Paradigm in Cancer Immunotherapy -
Source: Aurora BioPharma, Inc.